Skip to content

Fluorescent Cholangiography vs White Light for Bile Ducts Identification

Efficacy Of Near Infrared Incisionless Fluorescent Cholangiography (NIFC) During Laparoscopic Cholecystectomy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02702843
Enrollment
677
Registered
2016-03-09
Start date
2016-04-30
Completion date
2018-08-31
Last updated
2025-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholecystitis, Cholelithiasis

Brief summary

The Study is designed to compare the effectiveness of Near Infrared Fluorescence Cholangiography (NIFC) to standard white light imaging (WLI) in visualizing and identifying the main biliary and hepatic structures (Cystic Duct, Right Hepatic Duct, Common Hepatic Duct, Common Bile Duct, Cystic-CBD junction, Cystic-Gallbladder junction and any Accessory Ducts) during laparoscopic cholecystectomy. The aim is to demonstrate that NIFC performs better than standard white light (WLI) alone in visualizing and identifying extra-hepatobiliary structures (Cystic Duct, Right Hepatic Duct, Common Hepatic Duct, Common Bile Duct, Cystic-CBD junction, Cystic-Gallbladder junction, and any Accessory Ducts) before and after dissection during Laparoscopic Cholecystectomy (LC).

Detailed description

Recently, a novel technique to visualize structures using fluorescent light and intravenous dye has been developed. Near Infrared Incisionless Fluorescent Cholangiography (NIFC) is a medical imaging technique that uses fluorescence to detect properly labeled structures during surgery. NIFC is performed using imaging devices with the purpose of providing real-time simultaneous information from color reflectance images (white light) and fluorescence emission (near infrared light). One or more light sources are used to excite and illuminate the sample. Light is collected using optical filters that match the emission spectrum of the fluorophore. Imaging lenses and digital cameras are used to produce the final image. During laparoscopic cholecystectomies, the visualization of the extra-hepatic bile ducts with fluorescence is called Near Infrared Incisionless Fluorescent Cholangiography (NIFC). Fluorescence equipment and a dye are necessary in order to perform a NIFC, but the technique requires no radiation or incision. A fluorescence dye is administrated intravenously at least 45 minutes before the surgery, which is excreted by the liver and the bile duct The Study is designed to compare the effectiveness of Near Infrared Fluorescence Cholangiography (NIFC) to standard white light imaging (WLI) in visualizing and identifying the main biliary and hepatic structures (Cystic Duct, Right Hepatic Duct, Common Hepatic Duct, Common Bile Duct, Cystic-CBD junction, Cystic-Gallbladder junction and any Accessory Ducts) during laparoscopic cholecystectomy. Eligible patients will be identified through clinical and test evaluation. Eligibility will be verified by the patient's primary surgeon. The surgeon will determine the indication and date of the surgery. Once a patient is confirmed as eligible, the surgeon will introduce the study in detail. If after being introduced to the study and having had the opportunity to ask questions, the patient is willing to participate, he/she will be asked to review and sign the informed consent document . Upon entry in the clinical trial patients will be randomly allocated to the intervention arm. Data will be collected at enrolment time, during surgery, at the end of surgery and one week after surgery. Upon entry in the clinical trial, the master study database (REDCap, will randomly allocated patients to one of the study arms (1:1) within site (1:1) using a computer generated random sequence. This will provide an allocation sequence for each site. Once a patient is enrolled and a database file in REDCap is initiated for that patient, he/she will be assigned electronically to one of the study arms. Patient will be blind to the intervention but surgeon blinding will not be feasible due to the nature of the intervention. The study will involve a considerable number of surgeons in each site, which should compensate any potential bias of some of them in favor or against either approach.

Interventions

PROCEDURELaparoscopic cholecystectomy with Xenon light

Standard laparoscopic cholecystectomy with white light

PROCEDURELaparoscopic cholecystectomy (fluorescent cholangiography)

Laparoscopic cholecystectomy in infrared light after injection of indocyanine green pre-operatively.

Sponsors

Cedars-Sinai Medical Center
CollaboratorOTHER
Tokyo Medical University
CollaboratorOTHER
Asklepios Kliniken Hamburg GmbH
CollaboratorOTHER
Università degli Studi dell'Insubria
CollaboratorOTHER
University of Rostock
CollaboratorOTHER
Hospital de Clinicas José de San Martín
CollaboratorOTHER
The Cleveland Clinic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients of both genders 2. Minimum age: 18 years old 3. Spoken and written command of the language spoken in the country's center 4. Ability to understand and follow the study procedures and sign the informed consent

Exclusion criteria

1. Known allergies to iodides 2. Known history of coagulopathy 3. Known moderate or severe liver disease Women who are pregnant or breastfeeding, or for whom possibility of pregnancy was not ruled out

Design outcomes

Primary

MeasureTime frameDescription
Detection Rate of Common Bile Duct Before and After Dissection Using Near Infra-red LightImmediately before dissection (baseline) and immediately after dissection during the same surgical procedure.Detection rate of the common bile duct during laparoscopic cholecystectomy, defined as the proportion of patients in whom the common bile duct was visualized immediately before dissection (baseline) and immediately after dissection using near infrared light. The detection rate was calculated separately for each arm and reported as the percentage of patients with successful identification.

Countries

Argentina, Germany, Italy, Japan, United States

Participant flow

Participants by arm

ArmCount
Xenon Light
Laparoscopic cholecystectomy with Xenon Light Laparoscopic cholecystectomy with Xenon light: Standard laparoscopic cholecystectomy with white light
318
Near Infrared Light
Laparoscopic cholecystectomy with Near infrared light Laparoscopic cholecystectomy with Xenon light: Standard laparoscopic cholecystectomy with white light Laparoscopic cholecystectomy (fluorescent cholangiography): Laparoscopic cholecystectomy in infrared light after injection of indocyanine green pre-operatively.
321
Total639

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyInsufficient data to analyze1523

Baseline characteristics

CharacteristicXenon LightNear Infrared LightTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
57 Participants57 Participants114 Participants
Age, Categorical
Between 18 and 65 years
261 Participants264 Participants525 Participants
Age, Continuous48.5 years
STANDARD_DEVIATION 15.5
48.3 years
STANDARD_DEVIATION 15
48.4 years
STANDARD_DEVIATION 15.2
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
318 Participants321 Participants639 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
318 Participants321 Participants639 Participants
Race (NIH/OMB)
White
0 Participants0 Participants0 Participants
Region of Enrollment
Argentina
96 participants104 participants200 participants
Region of Enrollment
Germany
106 participants111 participants217 participants
Region of Enrollment
Italy
33 participants31 participants64 participants
Region of Enrollment
Japan
0 participants1 participants1 participants
Region of Enrollment
United States
83 participants74 participants157 participants
Sex: Female, Male
Female
181 Participants218 Participants399 Participants
Sex: Female, Male
Male
137 Participants103 Participants240 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
1 / 3180 / 321
other
Total, other adverse events
4 / 3181 / 321
serious
Total, serious adverse events
2 / 3180 / 321

Outcome results

Primary

Detection Rate of Common Bile Duct Before and After Dissection Using Near Infra-red Light

Detection rate of the common bile duct during laparoscopic cholecystectomy, defined as the proportion of patients in whom the common bile duct was visualized immediately before dissection (baseline) and immediately after dissection using near infrared light. The detection rate was calculated separately for each arm and reported as the percentage of patients with successful identification.

Time frame: Immediately before dissection (baseline) and immediately after dissection during the same surgical procedure.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Xenon LightDetection Rate of Common Bile Duct Before and After Dissection Using Near Infra-red LightBefore Dissection64 Participants
Xenon LightDetection Rate of Common Bile Duct Before and After Dissection Using Near Infra-red LightAfter Dissection159 Participants
Near Infrared LightDetection Rate of Common Bile Duct Before and After Dissection Using Near Infra-red LightBefore Dissection157 Participants
Near Infrared LightDetection Rate of Common Bile Duct Before and After Dissection Using Near Infra-red LightAfter Dissection243 Participants

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026